Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in advanced HER2-mutant non-small cell lung adenocarcinoma
ChiCTR1800020262Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800020262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020262.